Caris Life Sciences, the precision medicine pioneer, develops and delivers innovative solutions to revolutionize healthcare and improve the human condition.
Irving, TX
Joined March 2011
- Tweets7.4K
- Following2.9K
- Followers22.5K
- Likes1.9K
Caris Detect™ is a blood test designed to find cancer in early stages, when treatment is most effective and survival rates are highest.
Take a proactive step for your health today — get the answers you need to move forward.
Learn more at CarisDetect.com
What if an H&E slide could tell us more about a patient’s risk of breast cancer recurrence? Artificial intelligence is opening that door.
New research from the ECOG-ACRIN Cancer Research Group and Caris Life Sciences provides evidence for the image + clinical AI approach that helped lay the scientific foundation for Caris MI Clarity™ in HR+/HER2− early-stage breast cancer.
In an independent TAILORx validation cohort, an AI model combining H&E-derived image features with clinical information strongly distinguished between patients at higher versus lower risk of early distant recurrence.
That image + clinical approach subsequently evolved into Caris MI Clarity, bringing AI-powered recurrence risk assessment into clinical practice.
Learn more: ow.ly/bS5W5102bkL
Caris Life Sciences retweeted
On November 12th from 12-1PM ET, join Dr. George W. Sledge Jr., a prominent American Medical Oncologist and Breast Cancer Researcher, for a practical conversation.
To register, click here: prg.gnosishosting.net/Events…
Caris Detect is a blood test that looks for signs of early-stage cancer.
When cancer is growing in your body, it leaves tiny clues in your blood, and Caris Detect can find them. It can spot these clues even when the cancer is very small and just starting to grow and even more importantly, before it spreads. This is important because the earlier cancer is found, the better the chance of beating it.
Learn more and get the test at CarisDetect.com
Caris molecular profiling helps Dr. Christopher Vaughn uncover possible mutations within a patient’s tumor and identify potential clinical trial opportunities.
These insights help guide more informed, personalized treatment decisions.
Learn how molecular profiling shapes his approach to care: ow.ly/hTG850Z9wp9
Caris Life Sciences retweeted
Genomic testing changed early-stage #BreastCancer treatment, but why do some cancers still recur? This #BreastCancerAwarenessMonth, learn about EA1241, a study building on TAILORx and RxPONDER to help explain recurrence. #BCSM cc: @carisls, @SWOG bit.ly/EA1241
Caris Detect™ is the blood test designed to catch cancer in the early stages of the disease, including breast cancer before a physical exam may find it.
Caris Detect looks for tiny signals of all genetic material from cancer instead of just a limited portion of DNA to find cancer signals in early stage, when treatment is most effective.
55+ cancers. One blood draw.
Breast cancer included.
Know in early stage.
Learn more and get the test at: CarisDetect.com
The enhanced Caris Assure® test adds RNA-based fusion detection through a dedicated whole transcriptome workflow — providing insights that DNA profiling alone can miss. See what’s new. ow.ly/R1zU50ZYfSm
Could multimodal AI help identify which patients with early-stage HR+ breast cancer may benefit from extended endocrine therapy?
In an NSABP B-42 cohort, significant benefit was observed in about one-quarter of patients the models classified as both high risk for late distant recurrence and likely to benefit from extended therapy. #ESMOAI26.
ow.ly/Rqh15101alG
Can AI help characterize capecitabine response in ER+ breast cancer? The Caris-led CapeAI study used clinico-genomic and next-generation sequencing (NGS) features to classify response to this common chemotherapy.
In an independent validation cohort, patients predicted to respond had longer progression-free survival; in a Caris cohort, predicted responders had longer time to next treatment and longer overall survival. #ESMOAI26
ow.ly/BLHa5101alF
Our team is waiting to chat with you at booth 1021. Take the opportunity to network with Caris at ESMO 2026 (@myESMO). ow.ly/EBuM510196W
MI Cancer Seek® provides molecular profiling for solid tumors with FDA-approved CDx indications. Available for both adult and pediatric patients (ages 1+).
Learn more & view important product info: bit.ly/4lyGNTR
Fragmented genetic testing can limit insight into myeloid malignancies. Caris ChromoSeq consolidates multiple methods into one Whole Genome Sequencing (WGS) assay, delivering a comprehensive view to support diagnosis and risk stratification. Learn more: bit.ly/4ufznZw
Join Caris and other leaders from the global oncology community at ESMO 2026.
Discover the latest advancements in precision oncology, connect with our team at booth #1021 and learn how deeper molecular insights are helping support more informed treatment decisions.
Schedule a meeting: ow.ly/efEV50ZUEQN
#ESMOAI26
Your breast cancer journey is personal. Caris MI Clarity™ may help support a more informed conversation about your care plan by providing additional insight into your risk of breast cancer recurrence over time. Talk with your healthcare provider about MI Clarity. bit.ly/4n8Jb5f
At Caris, we’re committed to supporting patients throughout their cancer journey. In recognition of #BreastCancerAwarenessMonth, Dr.
@GeorgeSledge51 shares the top 3 things to do when diagnosed with breast cancer. Watch and learn more: bit.ly/44yVbFv
When treatment decisions can depend on a single molecular finding, confidence and accuracy matter. The goal is not simply to detect more signals — it's to deliver clinically actionable findings that can help physicians guide treatment decisions with confidence.
Learn more about Caris Assure®: ow.ly/p10r50ZBEIs
